Drugs / nL-ATN1-002
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07084311 | Oct 2024 → Nov 2026 expected | dentatorubral-pallidoluysian atrophy | n-Lorem Foundation | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT06706388 | Feb 2024 → Feb 2027 expected | dentatorubral-pallidoluysian atrophy | n-Lorem Foundation | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | nL-ATN1-002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07084311 ↗ |
| Modality | Antisense oligonucleotide | “Personalized antisense oligonucleotide” NCT07084311 ↗ |